Join Dr. Aude Ambresin in this live series, where we will explore how RetinAI Discovery is transforming the management of AMD in Real-World Clinical Setting. Register today to learn how AI can help optimize the patient journey, reduce the burden on healthcare professionals, and improve clinical outcomes.
18th March at 7 PM CET
Online
Join us live!
Ophthalmology is one of the busiest specialties, and the growing prevalence of Age-Related Macular Degeneration (AMD) is placing immense pressure on healthcare systems worldwide. With over 200 million individuals affected by AMD and approximately 25% of people aged 60+ living with early or intermediate stages, both patients and healthcare providers face significant challenges.
Join Dr. Aude Ambresin in this live series, where we will explore how RetinAI Discovery is transforming the management of AMD in Real-World Clinical Setting. Register today to learn how AI can help optimize the patient journey, reduce the burden on healthcare professionals, and improve clinical outcomes.
PD Dr. med. Aude Ambresin is an FMH-certified Ophthalmologist and Ophthalmic Surgeon with extensive expertise in retinal diseases. Currently leading the Medical Retina Unit Retina Research Center at Swiss Visio, Dr. Ambresin specializes in the management of complex retinal conditions, particularly Age-Related Macular Degeneration (AMD), and is dedicated to advancing the field through both clinical practice and cutting-edge research. With a focus on integrating innovative technologies to optimize patient care, including artificial intelligence and advanced imaging techniques such as adaptive optics, she plays a key role in improving AMD management, particularly for dry AMD, and driving forward retinal research initiatives.